First Citizens Bank & Trust Co. Boosts Stock Position in Eli Lilly and Company $LLY

Key Points

• First Citizens Bank & Trust Co. increased its holdings in Eli Lilly and Company by 13.0% in Q2, acquiring an additional 1,782 shares, bringing their total shares to 15,513, valued at approximately $12 million.
• Equities analysts have varying sentiments on Eli Lilly's stock, with some firms like Guggenheim maintaining a "buy" rating and setting a price target of $948, while others like Deutsche Bank reduced their target from $1,010 to $900.
• Insider trading activity included Director Gabrielle Sulzberger and CEO David Ricks purchasing shares, increasing their ownership stakes, indicating confidence in the company's prospects.

First Citizens Bank & Trust Co. lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,513 shares of the company's stock after purchasing an additional 1,782 shares during the quarter. First Citizens Bank & Trust Co.'s holdings in Eli Lilly and Company were worth $12,093,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of LLY. Roman Butler Fullerton & Co. increased its stake in shares of Eli Lilly and Company by 2.9% in the second quarter. Roman Butler Fullerton & Co. now owns 8,973 shares of the company's stock worth $7,293,000 after acquiring an additional 249 shares during the period. Cornerstone Advisory LLC increased its holdings in shares of Eli Lilly and Company by 0.6% during the 2nd quarter. Cornerstone Advisory LLC now owns 2,591 shares of the company's stock valued at $2,020,000 after purchasing an additional 15 shares in the last quarter. Paragon Advisors LLC lifted its stake in shares of Eli Lilly and Company by 1.2% in the 2nd quarter. Paragon Advisors LLC now owns 6,447 shares of the company's stock valued at $5,025,000 after purchasing an additional 78 shares during the period. Bleakley Financial Group LLC boosted its holdings in Eli Lilly and Company by 18.6% during the second quarter. Bleakley Financial Group LLC now owns 32,739 shares of the company's stock worth $25,521,000 after buying an additional 5,130 shares in the last quarter. Finally, Insight Advisors LLC PA grew its position in Eli Lilly and Company by 11.5% during the second quarter. Insight Advisors LLC PA now owns 1,234 shares of the company's stock valued at $961,000 after buying an additional 127 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Weiss Ratings restated a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Guggenheim reaffirmed a "buy" rating and set a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Finally, JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $938.61.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $808.68 on Thursday. The company has a market capitalization of $765.38 billion, a price-to-earnings ratio of 52.85, a PEG ratio of 1.14 and a beta of 0.47. The stock has a fifty day moving average of $762.81 and a two-hundred day moving average of $766.75. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.